SAREPTA THERAPEUTICS ($SRPT) is expected to release its quarterly earnings data on Monday, November 3rd after market close, per Finnhub. Analysts are expecting revenue of $342,827,518 and earnings of -$0.85 per share.
You can see Quiver Quantitative's $SRPT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SAREPTA THERAPEUTICS Hedge Fund Activity
We have seen 204 institutional investors add shares of SAREPTA THERAPEUTICS stock to their portfolio, and 244 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 8,562,435 shares (-94.5%) from their portfolio in Q2 2025, for an estimated $146,417,638
- D. E. SHAW & CO., INC. added 4,474,232 shares (+101548.6%) to their portfolio in Q2 2025, for an estimated $76,509,367
- JANUS HENDERSON GROUP PLC removed 3,325,968 shares (-98.8%) from their portfolio in Q2 2025, for an estimated $56,874,052
- AVORO CAPITAL ADVISORS LLC removed 2,674,835 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $45,739,678
- FARALLON CAPITAL MANAGEMENT LLC removed 2,341,424 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $40,038,350
- BLACKROCK, INC. added 2,208,354 shares (+22.3%) to their portfolio in Q2 2025, for an estimated $37,762,853
- EXOME ASSET MANAGEMENT LLC added 2,000,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $34,200,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SAREPTA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $SRPT in the last several months. We have seen 8 firms issue buy ratings on the stock, and 4 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 09/22/2025
- Guggenheim issued a "Buy" rating on 09/15/2025
- B of A Securities issued a "Underperform" rating on 08/21/2025
- Wells Fargo issued a "Overweight" rating on 08/07/2025
- Oppenheimer issued a "Outperform" rating on 07/29/2025
- Needham issued a "Underperform" rating on 07/29/2025
- Citigroup issued a "Sell" rating on 07/24/2025
To track analyst ratings and price targets for SAREPTA THERAPEUTICS, check out Quiver Quantitative's $SRPT forecast page.
SAREPTA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $SRPT recently. We have seen 26 analysts offer price targets for $SRPT in the last 6 months, with a median target of $21.0.
Here are some recent targets:
- Biren Amin from Piper Sandler set a target price of $16.0 on 10/30/2025
- Kostas Biliouris from BMO Capital set a target price of $50.0 on 09/22/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $22.0 on 09/15/2025
- Joseph Schwartz from Leerink Partners set a target price of $15.0 on 09/09/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $5.0 on 08/25/2025
- Tazeen Ahmad from B of A Securities set a target price of $16.0 on 08/21/2025
- David Hoang from Deutsche Bank set a target price of $12.0 on 08/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
